Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.33 |
| ▸ | CCNK | O75909 | 2/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111574 | 1.00 | CXCR4 (0.39) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL13696580 | 1.00 | CXCR4 (0.39) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL4124321 | 0.95 | CXCR4 (0.38) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL4122202 | 0.95 | CXCR4 (0.38) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL4110044 | 0.94 | CXCR4 (0.40) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL4116258 | 0.94 | CXCR4 (0.40) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL4110343 | 0.88 | CXCR4 (0.40) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL4105651 | 0.88 | CXCR4 (0.40) | CXCR4HRH4ALKCCNKCDK12 | |
| SCHEMBL4104403 | 0.88 | CXCR4 (0.37) | CXCR4HRH4ALKMRGPRX1 | |
| SCHEMBL13696579 | 0.88 | CXCR4 (0.37) | CXCR4HRH4ALKMRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | claimed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | claimed |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | ALLERGAN, INC. | 2007-08-30 | — | — | US | claimed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-7964191-B2 | Compositions and methods for the treatment of ophthalmic disease | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | CXCR4, CXCR1, CXCL12 | CXCR4 1/4885HRH4 152/4885ALK 222/4885 |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | CXCL12, CXCR4, PDE6C | CXCR4 2/4885HRH4 2600/4885ALK 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.